 This is a randomized, double-blind, vehicle-controlled, parallel-group comparison study to evaluate the safety and efficacy of Q301 Cream vs. vehicle in adult subjects with moderate to severe AD. Study drug Q301 Cream or vehicle will be administered topically twice a day for 8 consecutive weeks. 